Efficacy and Safety of Pembrolizumab Immunotherapy Combined with Lenvatinib Molecular Targeted Therapy in Patients with Advanced Liver Cancer/ZHANG Jianping， BIAN Weigang， CHEN Surong，CHEN Yan.//Medical Innovation ofChina，2025，22(19)： 045-048

    [Abstract] Objective： To investigate the clinical effect and safety of Pembrolizumab immunotherapy combined with Lenvatinib molecular targeted therapy inpatients with advanced liver cancer.Method：Atotalof 100 patients with advanced liver cancer in the Department of Oncology， Yancheng NO.1 People's Hospital from January 2021 to January 2O24 were selected as the research subjects.According to the random number table method，the patients were divided into the study group (n=5O) and the control group ( n =50).The control group was treated with Pembrolizumab，and the study group was treated with Pembrolizumab and Lenvatinib.The therapeutic effect and adversereactions of the two groups were compared，and the levels of tumor indicators [vascular endothelial growth factor (VEGF)，hypoxia-inducible factor-1α (HIF- ?l∝ )and proline hydroxylase 2 (PHD2)] in both groups were monitored before and after treatment.Result： The objective response rate and disease control rate of the study group were higher than those of the control group ( P lt;0.05).There were no statistically significant differences in the incidence of adverse reactions between the study group and the control group ( P gt;0.05).ThelevelsofVEGF ......